HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

fananserin

RN & structure given in first source

Also Known As:

2-(3-(4-(4-fluorophenyl)-1-piperazinyl)propyl)-2H-naphth(1,8-cd)isothiazole 1,1-dioxide; RP 62203; RP-62203; fananserine

Networked: 4 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Aromatic Hydrocarbons: 291
      - Polycyclic Aromatic Hydrocarbons: 2020
        Naphthalenes: 18
        fananserin: 4
- Sulfur Compounds: 278
  - Cyclic S-Oxides
    - fananserin: 4
Heterocyclic Compounds: 198
- Heterocyclic Oxides
  - Cyclic S-Oxides
    - fananserin: 4
Polycyclic Compounds: 6
- Polycyclic Aromatic Hydrocarbons: 2020
  - Naphthalenes: 18
    - fananserin: 4

Experts

1.	Semba, Jun'ichi: 1 article (02/2004)

Related Diseases

1.	Schizophrenia (Dementia Praecox) 03/01/1999 - "The authors' objective was to assess the potential efficacy of fananserin (RP62203), a potent antagonist at the D4 and serotonin2A (5-HT2A) receptors, on symptoms of schizophrenia. " 02/01/2004 - "Two D4 antagonists (L-745,879 and fananserine) failed to show clinical efficacy in schizophrenia. " 03/01/1999 - "Placebo-controlled study of the D4/5-HT2A antagonist fananserin in the treatment of schizophrenia."
2.	Psychomotor Agitation (Akathisia) 03/01/1999 - "The patients' extrapyramidal symptoms did not worsen during the trial, but the patients given fananserin had an increase in akathisia. "
3.	Sleep Wake Disorders 04/01/1992 - "RP 62203 could therefore be of clinical interest in the management of sleep disorders, particularly those developing within a psychiatric context."
4.	Catalepsy 02/19/1998 - "WAY-100635 (0.1-3 mg/kg, s.c.), ketanserin (0.1-3 mg/kg, s.c.), MDL 100,151 (0.3-3 mg/kg, s.c.) and fananserin (RP 62203; 3 mg/kg, s.c.) induced a significant catalepsy. "

Related Drugs and Biologics

1.	Serotonin 5-HT2 Receptor Antagonists
2.	fananserin
3.	Ketanserin
4.	MDL 100,151
5.	N- (2- (4- (2- methoxyphenyl)- 1- piperazinyl)ethyl)- N- (2- pyridinyl)cyclohexanecarboxamide